HIV Infections
Conditions
Keywords
HIV infection, neuropsychological adverse effects, Raltegravir
Brief summary
Open, multicenter, non randomized, single arm, pilot trial.
Detailed description
Open, multicenter, non randomized, single arm, pilot trial. The study is aimed at patients infected with HIV in triple antiretroviral therapy based on Dolutegravir (DTG) who experience neuropsychological adverse effects related to the treatment. After signing the informed consent, DTG will be replaced by Raltegravir (RAL) 1200 QD, maintaining the other two drugs that constituted the triple therapy established before the inclusion of the patient in the study.
Interventions
DRUGRaltegravir
DTG will be replaced by Raltegravir (RAL) 1200 QD, maintaining the other two drugs that constituted the triple therapy established before the inclusion of the patient in the study.
Sponsors
Merck Sharp & Dohme LLC
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Intervention model description
Multicenter, open, non-randomized pilot trial.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years. * Infection with chronic HIV-1. * On triple therapy antiretroviral therapy based on abacavir/lamivudine (ABC/3TC) or tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) or tenofovir alafenamide/emtricitabine (TAF/FTC), whose third component is DTG in a dose of 50 mg / day. * Presence of neuropsychiatric symptoms (insomnia, sleep disturbances, reduced concentration, dizziness, headaches, depression, restlessness or nervousness) with an intensity ≥ 2 on the DAIDS scale. * Written informed consent to participate in the study.
Exclusion criteria
* Pregnant women, nursing or of childbearing age who want to get pregnant. * Concomitant use of any medication with potential risk of interaction with the therapy under study. * Intolerance, hypersensitivity or previous resistance to the therapy under study or presence of any contraindication of it. * Subjects in therapy with immunosuppressants or chemotherapy with cytotoxics, including interferon and interleukin-2 at the time of their inclusion in the study. * Abuse of alcohol or any other substance that may interfere with adherence to treatment. * Subjects who are participating in any other clinical study with the exception of those in which the treatment under study has been suspended for more than 12 weeks. * AIDS event at the time of diagnosis of HIV infection or in the 3 months prior to its inclusion * Any other clinical condition or previous treatment that makes the subject unsuitable for the study or that compromises their ability to comply with the treatment dosing requirements. * History of mental illness or diagnosis of neuropsychological symptoms prior to the use of DTG. * Presence of genotypic mutations that confer resistance to ABC, TDF / TAF, 3TC or FTC. * Chronic liver disease in the cirrhosis phase (either by ultrasound criteria or fibroscan ≥ 14.5 KPa) * Consumption of tobacco ≥ 20 cigarettes / day. Additional
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate improvement in neuropsychiatric symptoms at 12 weeks (Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events) | 12 weeks | Evaluate improvement in neuropsychiatric symptoms: grade 1 to 4 of DAIDS scale. higher values represent a worse outcome |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Interruptions of the medication for any reason | 24 weeks | Interruptions of the medication due to adverse effects, virological failure, or any other reason |
| Change in quality of life (WHOQoL-bref questionnaire) | 24 weeks | World Health Organization Quality of Life: 1-100 in 4 domains. 100 best score |
| Variation of the result in the Hospital, Anxiety and Depression (HAD) scale | 24 weeks | Hospital, anxiety and depression: 0 y 7 indicates no case, between 8 & 10 indicates doubtful case and scores of 11 and above are possibly anxiety and depression cases. |
| Neuropsychiatric symptoms | 24 weeks | Presence and Intensity of neuropsychiatric symptoms (visual scale 0 to 10) |
| Variation of the result in the Epworth scale | 24 weeks | Diurnal drowsiness: If score is less than 6 points, daytime sleepiness is low or absent; between 7 and 8, is in the average of the population and if it is higher than 9 its drowsiness is excessive. |
| Variation of the result in the COLUMBIA-SUICIDE SEVERITY RATING (CSSR) scale | 24 weeks | COLUMBIA-SUICIDE SEVERITY RATING SCALE: progressive score depending of each question answer |
| Magnetic Resonance Imagigng (MRI) analysis for 10 of the patients recruited at the Costa del Sol Hospital (pilot subestudy) | 24 weeks | * Identify patterns of different metabolic marker 18F-fluorodeoxyglucose (18F-FDG) uptake in patients suffering from central nervous system toxicity in relation to the use of Dolutegravir after replacement with Raltegravir. * Observe if the anatomic-functional pattern of these patients changes after the substitution of Dolutegravir by Raltegravir. |
| Variation of the result on the Pittsburgh Sleep Quality Index (PSQI) scale | 24 weeks | Pittsburgh Sleep Quality Index: Score 0 to 21 points. 0 indicates ease of sleeping and 21 severe difficulty in all areas. |
Countries
Spain
Contacts
Primary ContactGloria Luque
Backup ContactAlejandro Pérez
Outcome results
None listed